Aims: We have previously reported 5-year follow-up data on the TIAregistry.org, an international prospective cohort in patients with transient ischemic attack (TIA) or minor stroke. We conducted a Japanese subgroup analysis because outcomes and predictors might differ according to ethnicities and regions. In this study, we compared the baseline and 5-year follow-up data of Japanese and non-Japanese patients with TIA or minor stroke.

Methods: Patients with TIA or minor ischemic stroke within 7 days after the onset were classified into two groups based on ethnicity, Japanese (n=345) and non-Japanese (n=3502); further, 5-year event rates were compared between the two groups. We also determined predictors of 5-year stroke for both groups.

Results: Vascular death and death from any cause were identified to be less prevalent, unlike stroke and intracranial hemorrhage, which was determined to be more prevalent in Japanese than in non-Japanese patients. Five-year rate of stroke was significantly higher in Japanese patients. Cumulative stroke and major cardiovascular event rates did not decline but instead linearly increased from 1 to 5 years in both groups. Baseline risk factors for 5-year stroke were as follows: age, diabetes, history of stroke or TIA, and congestive heart failure in Japanese patients. Independent predictors of 5-year stroke were large artery atherosclerosis, congestive heart failure, diabetes, and age in Japanese patients.

Conclusions: Recurrent stroke and intracranial hemorrhage were determined to be more prevalent at 5 years after TIA or minor stroke in Japanese patients than in non-Japanese patients. Strategies to mitigate the long-term risks of stroke, aside from adherence to current guidelines, should take Japanese-patient-specific residual risks into account.

Key words: Transient ischemic attack, Stroke, Risk factor, Predictor, Outcome

Abbreviations: GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Factor for Occluded Coronary Arteries; TOAST, Trial of Org 10172 in Acute Stroke Treatment
Introduction

The TIAregistry.org is an international, multi-center-cooperative, prospective registry of transient ischemic attack (TIA) or minor ischemic stroke within 7 days after the onset. In a previous Japanese subgroup analysis using the 1-year follow-up data of the TIAregistry.org, differences in risk factors, stroke subtypes, and outcome events were determined between Japanese and non-Japanese patients, and the predictors for recurrent stroke among Japanese patients included congestive heart failure (CHF) and regular alcohol drinking. However, the results were preliminary as the follow-up period was only 1 year. Thereafter, we reported the results of our analysis using the 5-year follow-up data in this registry and further showed a sustained risk of cardiovascular events over a period of 5 years.

Aim

We have conducted a Japanese subgroup analysis on the 5-year follow-up data obtained from the TIAregistry.org in order to compare the long-term outcomes and predictors between Japanese and non-Japanese patients with TIA or minor ischemic stroke.

Methods

Study Design

The methods used for patient recruitment and evaluation for the TIAregistry.org project have been described previously. The protocol has been approved by the local institutional review boards. All patients provided written or oral informed consent as per country regulation. Sites in the registry from 21 countries have been described previously. Sites with follow-up data on >50% of their enrolled patients at 5 years were included for the analysis in this report. These sites were identified to be academic centers distributed among Europe, Asia, and Latin America. Data collection has also been reported previously. They were collected prospectively using a Web-based case-report form at the time of evaluation of the qualifying event at baseline, 1, 3, and 12 months and every 12 months for 5 years.

Events and Outcomes

Primary outcome was a composite of death from cardiovascular causes, nonfatal stroke (ischemic or hemorrhagic), or nonfatal acute coronary syndrome. Definitions of primary outcome events have already been described. Secondary outcomes included individual components of the primary outcome, TIA recurrence, death from any cause, any bleeding, and the modified Rankin Scale (mRS) at last follow-up. TIA has been defined as new neurologic symptoms or deficits lasting <24 hours without new infarctions on neuroimaging. Bleeding was then categorized as severe or life-threatening, moderate, or mild as per the GUSTO definitions. Primary outcome and all bleeding events were adjudicated by two investigators according to the clinical records.

Statistical Analysis

Quantitative variables were expressed as means (±standard deviation) in case of normal distribution or median (interquartile range) if otherwise. Meanwhile, categorical variables were expressed as numbers (percentage). Shapiro-Wilk test was utilized to graphically assess the normality of distributions. Baseline characteristics and medication use at discharge and at 1 and 5 years were compared between Japanese and non-Japanese patients. All comparisons between the two groups were adjusted for age and sex by using the analysis of covariance for quantitative variables, logistic regression models for binary variables, and multinomial regression models for categorical variables.

The 5-year event rates were then compared between the two groups using the Cox proportional-hazards regression model, which was adjusted for age, sex, mRS, and ABCD² score. Non-Japanese patients were used as a reference in calculating the hazard ratios as effect size measures, with 95% confidence interval. Cumulative event curves were constructed using the Kaplan–Meier method.

The ABCD² score, acute infarctions identified on brain imaging, and probable causes of initial TIA or minor stroke according to the TOAST classification have been tested with stroke recurrence using Cox proportional-hazards model in the two groups separately. The proportional-hazards assumption was verified using the Schoenfeld residuals.

We then identified the independent predictors of 5-year stroke by first establishing age-, sex- and mRS-adjusted Cox proportional-hazards regression models in Japanese and non-Japanese patients separately. Candidate predictors were as follows: demographic characteristics, medical history, mRS, and major investigational findings. We then performed region-specific
stepwise-backward multivariable Cox proportional-hazards regression analysis by including all candidate predictors associated with outcomes at age-, sex- and mRS-adjusted $p$-value < 0.10. Age and sex were integrated into the model, and the removal criterion ($p$-value from the Wald test) of 0.05 was utilized. Before multivariable prognostic models are developed, we first examined the proportional-hazards assumptions for each candidate predictor using the Schoenfeld residuals plots, log-linearity assumption for continuous candidate predictors by calculating the variance inflation factors. Estimates obtained from the different imputed data sets were integrated using Rubin’s rules. The predictive ability of the models was then calculated in Japanese and non-Japanese patients by using Harrell’s C-statistic.

Statistical testing was performed at a two-tailed $\alpha$ level of 0.05. Data were analyzed using SAS software package, release 9.3 (SAS Institute, Cary, NC).

### Results

#### Background Characteristics

Patients with TIA or minor ischemic stroke within 7 days after the onset were classified into two groups based on ethnicity, Japanese ($n=345$) and non-Japanese ($n=3502$). Non-Japanese patients included were as follows: 537 Asian patients (China, $n=347$; Korea, $n=99$; Taiwan, $n=66$; and Lebanon, $n=25$) and 2965 non-Asian patients (Germany, $n=641$; France, $n=640$; Spain, $n=555$; Czech, $n=516$; UK, $n=213$; Portugal, $n=181$; Italy, $n=117$; Ireland, $n=72$; and Mexico, $n=30$). The Japanese patients were older, and more frequently are males, current cigarette smokers, regular alcohol drinkers, and with a history of stroke or TIA, but they had less hypertension, dyslipidemia, and coronary artery disease compared to non-Japanese patients (Table 1). In Japanese patients, ABCD2 scores 1–3 were found to be less common, but ABCD2 scores 6 and 7 were more common (Table 2). Regarding TOAST classification, small vessel occlusion was more common, but undetermined etiology was less common in Japanese patients (Table 2). Regarding brain and vascular imaging, Japanese patients frequently had acute infarctions and intracranial arterial stenoses but less frequently had extracranial arterial stenoses (Table 2).

#### Medication Use

In Japanese patients, the use of antiplatelet agents was less common after 1 year, while the use of anticoagulants with and without antiplatelet agents, which was more common after 1 year and at 5 years (Table 3). Further, the use of lipid-lowering agents was less common after 1 year and at 5 years unlike glucose-lowering agents, which were commonly used after 5 years in Japanese patients (Table 3).

#### Five-Year Event Rate

Vascular death, death from any cause, and TIA were identified to be less prevalent, whereas nonfatal stroke and intracranial hemorrhage were more prevalent in Japanese patients than in non-Japanese patients (Table 4). Kaplan-Meier curves at 5 years showed non-significantly higher major cardiovascular event rates (Fig. 1) and significantly higher stroke rates in

---

Table 1. Background characteristics at baseline

|                         | Japanese | Non-Japanese | $p$-value |
|-------------------------|----------|--------------|-----------|
| Age, mean (SD), year    | 68.1 (11.2) | 66.3 (13.4) | 0.005     |
| Male sex                | 244/345 (70.7%) | 2051/3496 (58.7%) | <0.001    |
| Hypertension            | 224/345 (64.9%) | 2483/3502 (71.1%) | <0.001    |
| Diabetes                | 73/345 (21.2%) | 654/3487 (18.8%) | 0.51      |
| Dyslipidemia            | 177/345 (51.3%) | 2532/3502 (72.3%) | <0.001    |
| Current smoker          | 92/345 (26.7%) | 743/3546 (21.5%) | 0.005     |
| Regular alcohol consumption | 133/345 (38.6%) | 66/3456 (19.2%) | <0.001    |
| Physical activity       | 88/345 (25.7%) | 713/3369 (21.2%) | 0.045     |
| Atrial fibrillation     | 39/345 (9.0%) | 395/3491 (8.5%) | 0.12      |
| History of stroke or transient ischemic attack | 90/345 (26.1%) | 568/3502 (16.2%) | <0.001    |
| Coronary artery disease | 30/344 (8.7%) | 451/3489 (12.9%) | 0.005     |
| Peripheral artery disease | 9/345 (2.6%) | 104/3474 (3.0%) | 0.53      |
| Congestive heart failure | 8/345 (2.3%) | 101/3491 (2.9%) | 0.55      |

$\dagger$ Physical activity was defined as any activity performed during at least 4 hours or more per week.
Table 2. Baseline ABCD² score, TOAST classification, and brain and vascular imaging

|                      | Japanese | Non-Japanese | P-value* |
|----------------------|----------|--------------|----------|
| ABCD² score          |          |              |          |
| 0-3                  | 65/315 (20.6%) | 1038/3101 (33.5%) | <0.001   |
| 4-5                  | 161/316 (50.9%) | 1480/3101 (47.7%) |          |
| 6-7                  | 90/316 (28.5%)  | 583/3101 (18.8%)  |          |
| TOAST classification |          |              |          |
|                      |          |              |          |
| Large artery atherosclerosis | 86/345 (24.9%) | 790/3213 (24.6%) | <0.001   |
| Small vessel occlusion | 133/345 (38.6%) | 630/3213 (19.2%) |          |
| Cardioembolism       | 56/345 (16.2%)  | 506/3213 (15.7%)  |          |
| Other determined causes | 26/345 (7.6%)  | 170/3213 (5.3%)   |          |
| Undetermined         | 45/345 (13.0%)  | 1117/3213 (34.8%) |          |
| Infarct on CT or MRI | 270/345 (78.3%) | 1460/3349 (43.6%) | <0.001   |
| Extracranial stenosis >50% | 37/318 (11.6%)  | 513/3183 (16.1%)  | 0.010    |
| Intracranial stenosis >50% | 67/341 (19.7%)  | 381/2874 (13.3%)  | 0.007    |

*Adjusted by age and sex

Table 3. Medication use at 1 and 5 years

| Medication                          | Japanese | Non-Japanese | At 1 year | At 5 years |
|-------------------------------------|----------|--------------|-----------|------------|
| Antiplatelet therapy                | 249/336 (74.1%)* | 2493/3102 (80.4%) | 199/277 (71.8%) | 1724/2353 (73.3%) |
| Anticoagulant therapy               | 90/337 (26.7%)** | 511/3087 (16.6%) | 75/277 (27.1%)** | 386/2355 (16.4%) |
| Antiplatelet and anticoagulant therapies | 21/340 (6.2%)** | 75/3187 (2.4%) | 17/302 (5.6%)** | 45/2406 (1.9%) |
| Lipid-lowering therapy              | 178/337 (52.8%)** | 2184/3068 (71.2%) | 162/277 (58.5%)* | 1566/2356 (66.5%) |
| Glucose-lowering therapy            | 66/336 (19.6%) | 520/3055 (17.0%) | 66/277 (23.8%)* | 413/2353 (14.6%) |

Shown are cumulative frequencies at different time points.
*Age- and sex-adjusted p<0.05  **Age- and sex-adjusted p<0.0005

Table 4. Primary and secondary outcomes

|                     | Japanese | Non-Japanese | HR (95% CI) | P-value |
|---------------------|----------|--------------|-------------|---------|
| Primary outcome     |          |              |             |         |
| Major CV events     | 55 (16.6%) | 414 (12.9%)  | 1.01 (0.75-1.38) | 0.93    |
| Vascular death      | 3 (0.9%)  | 93 (3.0%)    | 0.031 (0.16-0.64) | 0.01    |
| Nonfatal stroke     | 48 (14.4%) | 253 (7.9%)   | 1.54 (1.10-2.15) | 0.013   |
| Nonfatal ACS        | 6 (1.9%)  | 73 (2.4%)    | 0.56 (0.22-1.40) | 0.21    |
| Secondary outcome   |          |              |             |         |
| Any death           | 27 (8.1%) | 346 (10.9%)  | 0.60 (0.40-0.91) | 0.016   |
| Stroke              | 49 (14.7%) | 296 (9.2%)  | 1.28 (0.92-1.78) | 0.15    |
| TIA                 | 11 (3.3%) | 296 (9.0%)  | 0.45 (0.25-0.84) | 0.011   |
| Intracranial hemorrhage | 11 (3.4%) | 28 (0.9%)   | 2.52 (1.09-5.81) | 0.030   |
| Major bleeding      | 12 (3.8%) | 41 (1.4%)    | 1.97 (0.92-4.24) | 0.083   |

Data adjusted by age, sex, modified Rankin Scale score, and ABCD² score.
Abbreviations: HR; hazard ratio, CI; confidence interval, CV; cardiovascular, ACS; acute coronary syndrome, TIA: transient ischemic attack
tor of recurrent stroke after 5 years in a subgroup analysis, according to the TOAST classification at baseline (Fig. 3). Age, diabetes, history of stroke or TIA, coronary artery disease, and CHF at baseline were risk factors of recurrent stroke after 5 years among Japanese patients (Table 5). The Cox proportional-hazards regression model demonstrated that

Japanese patients (Fig. 2). Recurrent stroke rates were 8.4% and 4.8% at 1 year and 14.7% and 9.2% at 5 years in Japanese and non-Japanese patients, respectively.

Risk Factors and Predictors for 5-Year Stroke
Large artery atherosclerosis (LAA) was a predic-

Fig. 1. Kaplan–Meier curves of major cardiovascular events
The rate of major cardiovascular events was non-significantly higher in Japanese patients. Cumulative stroke rate curves did not decline but linearly increased in parallel during the second to fifth year in both Japanese and non-Japanese patients.

Fig. 2. Kaplan–Meier curves of recurrent stroke
The stroke rate was significantly higher in Japanese patients. Cumulative stroke rate curves did not decline but linearly increased in parallel during the second to fifth year in both Japanese and non-Japanese patients.
The use of antiplatelet drugs was less common unlike anticoagulants, which were determined to be commonly used among Japanese patients. Using antiplatelet drugs has declined during the 1- to 5-year follow-up among both Japanese and non-Japanese patients. Discontinuation of antiplatelet therapy may increase the risk of stroke recurrence5). Prescription rate of anticoagulants was found to be higher than the rates of atrial fibrillation and cardioembolism at baseline among Japanese patients, suggesting that anticoagulants were used in patients with other determined causes.

**Discussion**

Differences in the baseline risk factors between Japanese and non-Japanese patients in this study were determined to be similar to those obtained in the 1-year follow-up analysis reported previously, since 80% of the patients in the 1-year follow-up study were selected in this study1, 3). The higher proportions of AIS and high-risk TIA in Japanese patients suggest that we have recruited exclusively admitted patients with AIS and high-risk TIA but not recruited lower-risk TIA because of few TIA clinics in Japan2).

The use of antiplatelet drugs was less common unlike anticoagulants, which were determined to be commonly used among Japanese patients. Using antiplatelet drugs has declined during the 1- to 5-year follow-up among both Japanese and non-Japanese patients. Discontinuation of antiplatelet therapy may increase the risk of stroke recurrence5). Prescription rate of anticoagulants was found to be higher than the rates of atrial fibrillation and cardioembolism at baseline among Japanese patients, suggesting that anticoagulants were used in patients with other determined causes.

**Table 5.** Risk of 5-year stroke by baseline characteristics

|                      | Japanese | Non-Japanese |
|----------------------|----------|--------------|
| **Age (per 10 years)** | 1.35 (1.02-1.79) | 1.25 (1.13-1.37) |
| Men                  | 1.40 (0.73-2.69) | 1.32 (1.04-1.69) |
| Hypertension         | 1.58 (0.82-3.03) | 1.24 (0.92-1.67) |
| Diabetes             | 2.03 (1.13-3.66) | 1.56 (1.20-2.03) |
| Dyslipidemia         | 1.14 (0.65-1.99) | 0.97 (0.74-1.28) |
| Current smoker       | 1.51 (0.74-3.07) | 1.15 (0.83-1.59) |
| Regular alcohol consumption | 1.60 (0.91-2.81) | 0.96 (0.71-1.29) |
| History of stroke or TIA | 1.86 (1.05-3.30) | 1.69 (1.29-2.20) |
| Coronary artery disease | 2.15 (1.01-4.59) | 1.19 (0.86-1.63) |
| Peripheral artery disease | 1.06 (0.15-7.68) | 1.33 (0.74-2.37) |
| Congestive heart failure | 4.54 (1.63-12.64) | 1.46 (0.83-2.57) |

Data adjusted by age, sex, and modified Rankin Scale score.

CHF, diabetes, and age were independent predictors for recurrent stroke after 5 years **(Table 6)***.
higher with combination of anticoagulants and antiplatelet drugs than with antiplatelet drugs alone. Therefore, the risk-benefit of antithrombotics should be carefully balanced in Japanese patients.

The rate of major cardiovascular events was non-significantly higher, and the stroke rate was significantly higher in Japanese patients. This may be explained mainly by the higher stroke risk among Japanese patients selected in this study. Cumulative stroke rate curves did not decline but instead linearly increased in parallel during the second to fifth year in both Japanese and non-Japanese patients. The risk factors for 5-year stroke at baseline were age, diabetes, history of stroke or TIA, and CHF, whereas the independent predictors for 5-year stroke were age, LAA, CHF, and diabetes in Japanese patients. LAA, CHF, and diabetes were also identified predictors for 1-year stroke in Japanese patients.

In the TIAregistry.org, the 1-year stroke risk by TOAST classification was significantly high both in Japanese and non-Japanese patients with LAA. In this 5-year follow-up study, LAA was again an independent predictor for stroke recurrence at 5 years in Japanese patients. In the comparison between Asian and non-Asian patients in the TIAregistry.org 5-year follow-up study, although an analysis according to the TOAST classification was not performed, intracranial arterial stenosis was also determined as an independent predictor of the primary outcome in Asian patients (under article submission). LAA is a poly-vascular disease, which includes atherothrombotic stroke, TIA, coronary artery disease, and peripheral artery disease, and the risk of vascular events in patients with LAA increases as the number of involved vascular beds increases. Therefore, to reduce the residual risk of

| Table 6. Independent predictors for 5-year stroke in Japanese and non-Japanese patients |
|-----------------|-----------------|-----------------|
|                 | HR (95% CI)     | P-value         |
| Japanese        |                 |                 |
| Congestive heart failure | 4.43 (1.55-12.66) | 0.006          |
| Diabetes        | 2.31 (1.26-4.24) | 0.007          |
| Age (per 10 years) | 1.38 (1.03-1.85) | 0.031          |
| Non-Japanese    |                 |                 |
| Diabetes        | 1.48 (1.14-1.92) | 0.003          |
| Age (per 10 years) | 1.16 (1.05-1.28) | 0.003          |
| Single acute infarct | 1.39 (1.05-1.85) | 0.022          |
| Multiple acute infarct | 1.73 (1.28-2.35) | <0.001         |
| Extracranial stenosis >50% | 1.60 (1.21-2.13) | 0.001          |
| Cardioembolism  | 1.59 (1.10-2.30) | 0.013          |

Cox proportional hazard regression model was used for analysis. The Haller C index for stroke recurrence was 0.69 (95% CI: 0.61-0.77) and 0.68 (95% CI: 0.65-0.71) for Japanese and non-Japanese patients, respectively.
In our previous 1-year follow-up study, CHF was the strongest predictor for stroke recurrence in Japanese patients\(^3\). In this 5-year follow-up study, CHF was again the strongest predictor for 5-year stroke in Japanese patients. It is well known that CHF is a risk factor for stroke in patients with atrial fibrillation, although CHF can cause stroke without atrial fibrillation and, therefore, should be considered as an independent risk factor for stroke\(^4\). The mechanism of stroke in CHF patients is primarily embolic, and the risk of stroke is associated with left ventricular dysfunction and dilatation\(^4\). The number of patients with CHF is increasing along with the increase of the elderly population\(^5, 6\). The higher mean age of Japanese patients may contribute to the increased risk of recurrent stroke induced by heart failure\(^7, 8\).

In our previous 1-year follow-up study, diabetes was a non-significant predictor for stroke recurrence in Japanese patients\(^2\). In this 5-year follow-up study, diabetes was identified as a significant predictor for stroke recurrence. The number of patients with diabetes has remarkably increased due to the Westernization of diet and increasing number of elderly subjects in Japan\(^9, 10\). Therefore, diabetes as a risk factor for stroke is becoming more important, but the management of diabetes for stroke prevention is still insufficient\(^11\). The J-DOIT 3 trial showed that multiple aggressive interventions dramatically reduced the stroke risk compared with conventional treatments in Japanese diabetic patients\(^12\). The results of J-DOIT 3 suggest that more intensive total risk management in addition to the current guidelines can reduce the residual risk of recurrent stroke also in patients with TIA and minor stroke.

There are limitations in this study. First, owing to its observational nature, even after extensive adjustment, residual confounding cannot be ruled out. Second, because the participating sites were not selected randomly, the cohort analyzed in this study could differ from the general TIA/stroke population. Third, the relatively small sample of Japanese patients may have caused type II errors in our statistical analysis, which may negatively affect our findings on the risk factors and predictors.

**Conclusion**

Recurrences of stroke and intracranial hemorrhage at 1 and 5 years after TIA or minor stroke were determined to be more frequent in Japanese patients than in non-Japanese patients. Predictors for stroke recurrence were identified as follows: LAA, CHF, and diabetes in Japanese patients with acute cerebrovascular syndrome. Strategies to reduce the long-term risk of stroke, aside from adherence to the current guidelines, should take Japanese-patient-specific residual risks into account. Our Japanese-specific data would contribute to the development of long-term stroke prevention strategies specifically tailored to Japanese patients with TIA or minor stroke as well as projects for the appropriate allocation of resources for their care.

**Acknowledgements**

We would like to thank all collaborators of TIAregistry.org for patients' recruitment, follow-up, and data collection.

**Funding Source**

This study was supported by a grant from the Japanese Cardiovascular Research Foundation.

**Conflicts of Interest Statement**

The authors declare that there is no conflict of interest.

**References**

1) Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut E, and Wong LKS; TIAregistry.org Investigators: One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med, 2016; 374: 1533-1542

2) Uchiyama S, Hoshino T, Sissani L, Monteiro Tavares L, Kamiyama K, Nakase T, Kitagawa K, Minematsu K, Todo K, Okada Y, Nakagawara J, Nagata K, Yamagami H, Yamaguchi T, and Amarenco P: Japanese versus non-Japanese patients with transient ischemic attack or minor stroke: subanalysis of TIA registry.org. J Stroke Cerebrovasc Dis, 2019; 28: 2232-2241

3) Amarenco P, Lavallée PC, Monteiro Tavares L, Labreuche J, Albers GW, Abbadou H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Krafl M, Lin HE, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut E, Wang Y, and Wong LKS; TIAregistry.org Investigators: Five-year risk of stroke after TIA or minor stroke. N Engl J Med, 2018; 378: 2182-2190

4) Uehara T, Minematsu K, Ohara T, Okada Y, Hasegawa Y, Tanahashi N, Suzuki A, Nakagawara J, Arii K, Nagahiro S, Ogasawara K, Uchiyama S, Matsumoto M, Iihara K,
Toyoda K, and Minematsu K; PROMISE-TIA study Investigators: Incidence, predictors, and etiology of subsequent ischemic stroke within one year after transient ischemic attack. Int J Stroke, 2017; 12: 84-89
5) Ostergaard K, Pottegaard A, Hallas J, Bak S, Christensen RD, and Gaist D: Discontinuation of antiplatelet treatment and risk of recurrent stroke and all-cause death: a cohort study. Neuroepidemiology, 2014; 43: 57-64
6) Nezu T, Hosomi N, Lip GY, Aoki S, Shimura R, Maruyama H, Yagita Y, Matsumoto M, and Kobayashi S; Japan Standard Stroke Registry Group: Temporal trends in severity and prior antithrombotic use among acute ischemic stroke patients in Japan. Circ J, 2016; 80: 2033-2036
7) Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson LM, Truelsen T, O’Donnell M, Venketasubramanian N, Baker-Collo S, Lawes CM, Wang W, Shinozawa Y, Witt E, Ezzati M, Naghavi M, and Murray C; Global Burden of Diseases, Injuries, Risk Factors Study 2010 (GBD 2010); GBD Stroke Experts Group: Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet Glob Health, 2013; 1: e259-e281
8) Hata J, Ninomiya T, Hirakawa Y, Nagata M, Mukai N, Gotoh S, Fukuhara M, Ikeda F, Shikata K, Yoshida D, Yonemoto K, Kamouchi M, Kitazono T, and Kiyohara Y; Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study (1961-2009). Circulation, 2013; 128: 1198-1205
9) Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi J, and Minematsu K; Bleeding with Anti-thrombotic Therapy (BAT) Study Group: Dual anti-thrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective multicenter observational study. Stroke, 2008; 39: 1740-1745
10) Shen AY, Yao JF, Brar SS, Jorgensen MB, and Chen W: Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol, 2007; 50: 309-315
11) Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liu CS, Richard AJ, Rother J, and Wilson PWF; REACH Registry Investigators: International prevalence, recognition and treatment of cardiovascular risk factors in out-patients with atherosclerosis. JAMA, 2006; 295: 180-189
12) Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Maruyama H, Origasa H, Minematsu K, Uchiyama S, Nakamura M, and Matsumoto M; J-STARS collaborators: Cumulative effect of LDL and CRP levels on recurrent stroke and TIA. J Atheroscler Thromb, 2019; 26: 432-441
13) Nezu T, Hosomi N, Kitagawa K, Nagai Y, Nakagawa Y, Aoki S, Kagimura T, Maruyama H, Origasa H, Minematsu K, Uchiyama S, and Matsumoto M; J-STARS collaborators: Effect of statin on stroke recurrence prevention at different infarction locations: a post-hoc analysis of J-STARS study. J Atheroscler Thromb, 2020; 27: 524-533
14) Witt BJ, Brown RD Jr, Jacobsen SJ, Weston SA, Ballman KV, Myerden RA, and Roger V: Ischemic stroke after heart failure: a community-based study. Am Heart J, 2006; 152: 102-109
15) Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, nodsi S, Lam CSP, Sato N, Shah AN, and Hung MC: The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol, 2014; 63: 1123-1133
16) Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Haipern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT; Lichtman JH, Liaseth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Morler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Panyter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Varani SS, Wong ND, Woo D, and Turner MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics – 2014 update: a report from the American Heart Association. Circulation, 2014; 129: e28-e292
17) Sakata Y and Shimokawa H: Epidemiology of heart failure in Asia. Circ J, 2013; 77: 2209-2217
18) Shimokawa H, Miura M, Nochioka K, and Sakata Y: Heart failure as a general pandemic in Asia. Eur J Heart Fail, 2015; 17: 884-892
19) Kabeya Y, Kato M, Isogawa A, Takahashi Y, Matsushita Y, Goto A, Iso H, Inoue M, Mizoue T, Tsugane S, Kadowaki T, and Noda M: Descriptive epidemiology of diabetes prevalence and HbA1c distribution based on a self-reported questionnaire and a health checkup in the JPHC Diabetes Study. J Epidemiol, 2014; 24: 460-468
20) Goto A, Noda M, Inoue M, Goto M, and Charvat H: Increasing number of diabetes in Japan: is this trend real? Intern Med, 2016; 55: 1827-1830
21) Uchiyama S, Shibata Y, Hirabayashi T, Mihara B, Hamashige N, Kitagawa K, Goto S, Origasa H, Shimada K, Kobayashi H, Izoozaki M, Ikeda Y; J-TRACE Investigators: Risk factor profiles of stroke, myocardial infarction, and atrial fibrillation: a Japanese Multicenter Cooperative Registry. J Stroke Cerebrovasc Dis, 2010; 19: 190-197
22) Ueki K, Sasaki T, Okazaki Y, Kato M, Okahata S, Katsumata H, Haraguchi M, Morita A, Ohashi K, Harata K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, and Kadowaki T; J-DOIT3 Study Group: Effect of intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomized controlled trial. Lancet Diabetes Endocrinol, 2017; 5: 951-964